arsenic has been researched along with idelalisib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aguilera-Montilla, N; Amigo-Jiménez, I; Bailón, E; García-Marco, JA; García-Pardo, A; Terol, MJ | 1 |
| Bashash, D; Dadashi, M; Ghaffari, SH; Momeny, M; Safa, M; Safaroghli-Azar, A | 1 |
2 other study(ies) available for arsenic and idelalisib
| Article | Year |
|---|---|
Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Communication; Cell Line; Class I Phosphatidylinositol 3-Kinases; Coculture Techniques; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mesenchymal Stem Cells; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Oxides; Phosphorylation; Protein Kinase C beta; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolinones; RNA Interference; Signal Transduction; STAT3 Transcription Factor; Staurosporine; Time Factors; Transfection; Tumor Cells, Cultured; Tumor Microenvironment; Up-Regulation | 2015 |
Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation; Humans; Inhibitor of Apoptosis Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Purines; Quinazolinones; Survivin | 2017 |